BRIDGEBIO PHARMA

Lobbying client · California · filed 2025 to 2026

Biopharmaceutical manufacturer.

$2,990,000 Reported spend

17 Filings counted

3 Outside firms hired

10 Bills named

Spend is reported income plus in-house expenses across 17 filings. 2 further filings for this client were restated by a later amendment and are left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 4 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as BRIDGEBIO PHARMA, INC.

Who filed for this client 4

BRIDGEBIO PHARMA, INC. $2,620,000 In-house, the client's own filings · 7 filings
MARSHALL & POPP, LLC $320,000 Outside firm · 7 filings
THORN RUN PARTNERS $30,000 Outside firm · 1 filing
TODD STRATEGY GROUP $20,000 Outside firm · 2 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

Bills named in these filings 10

H.R. 1262
Mikaela Naylon Give Kids a Chance Act

5 filings
H.R. 1532
Scientific EXPERT Act of 2025

5 filings
S. 822
Scientific EXPERT Act of 2025

5 filings
H.R. 1
One Big Beautiful Bill Act

3 filings
H.R. 1414
Cameron’s Law

3 filings
H.R. 10359
Priority for Pediatric Cures Act

1 filing
H.R. 1968
Full-Year Continuing Appropriations and Extensions Act, 2025

1 filing
H.R. 4317
PBM Reform Act of 2025

1 filing
H.R. 7148
Consolidated Appropriations Act, 2026

1 filing
S. 932
Give Kids a Chance Act of 2025

1 filing

Reported by year 2 years

2026 $1,610,000 6 filings
2025 $1,380,000 11 filings

Issues lobbied 5

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 5

HOUSE OF REPRESENTATIVES 15
SENATE 15
Food & Drug Administration (FDA) 6
Centers For Medicare and Medicaid Services (CMS) 5
Health & Human Services, Dept of (HHS) 2

Recent filings 19 total

Q3 report

MARSHALL & POPP, LLC

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 20, 2026

View → Q3 report

BRIDGEBIO PHARMA, INC.

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $510,000 expenses · posted Oct 19, 2026

View → Q2 report

BRIDGEBIO PHARMA, INC.

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $500,000 expenses · posted Jul 20, 2026

View → Q4 amendment

BRIDGEBIO PHARMA, INC.

4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $280,000 expenses · posted Jul 17, 2026

View → Q2 report

MARSHALL & POPP, LLC

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 9, 2026

View → Q1 report

BRIDGEBIO PHARMA, INC.

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $420,000 expenses · posted Apr 20, 2026

View → Q1 report

MARSHALL & POPP, LLC

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $60,000 income · posted Apr 17, 2026

View → Q4 report

BRIDGEBIO PHARMA, INC. Amended

4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $270,000 expenses · posted Jan 20, 2026

View → Q4 report

MARSHALL & POPP, LLC

4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $60,000 income · posted Jan 16, 2026

View → Q3 report

BRIDGEBIO PHARMA, INC.

3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $270,000 expenses · posted Oct 20, 2025

View → Q3 report

MARSHALL & POPP, LLC

3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 20, 2025

View → Q2 termination

TODD STRATEGY GROUP

2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $20,000 income · posted Oct 11, 2025

View → Q2 report

TODD STRATEGY GROUP Amended

2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $20,000 income · posted Jul 30, 2025

View → Registration

TODD STRATEGY GROUP

2nd Quarter 2025 (Apr 1 - June 30) · posted Jul 21, 2025

View → Q2 report

MARSHALL & POPP, LLC

2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $20,000 income · posted Jul 21, 2025

View → Q2 report

BRIDGEBIO PHARMA, INC.

2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $320,000 expenses · posted Jul 17, 2025

View → Registration

MARSHALL & POPP, LLC

2nd Quarter 2025 (Apr 1 - June 30) · posted Jul 10, 2025

View → Q1 report

BRIDGEBIO PHARMA, INC.

1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $320,000 expenses · posted Apr 18, 2025

View → Q1 termination

THORN RUN PARTNERS

1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $30,000 income · posted Mar 13, 2025

View →

Keep going

Filings through October 20, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.